CCND1 and head and neck squamous cell carcinoma: SVC112, an elongation inhibitor, significantly suppressed the expression of c-Myc, CCND1, and Sox2 in HNSCC cells and CSCs across in vitro, ex vivo, and in vivo models. When combined with cisplatin and radiation therapy, SVC112 further reduced tumor growth in vivo.